AI assistant
MEMPHASYS LIMITED. — Declaration of Voting Results & Voting Rights Announcements 2012
Jun 21, 2012
65314_rns_2012-06-21_78fe328d-4b68-4d7f-9a2d-9163675f5fc7.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in viewerOpens in your device viewer
==> picture [184 x 24] intentionally omitted <==
==> picture [184 x 23] intentionally omitted <==
==> picture [184 x 24] intentionally omitted <==
==> picture [184 x 23] intentionally omitted <==
FOR IMMEDIATE RELEASE
Results of General Meeting
Sydney, Australia 22 June 2012 - In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, NuSep Holding Limited advises that the result of each resolution that was tabled at the General Meeting is as set out in the summary below. The number of proxy votes and their direction is as at the close of proxies on 20 June 2012.
.
Resolution 1- Removal of RSM Bird Cameron as Auditor of the Company
Total number of proxy votes
| Proxy Votes for the Resolution | 44,899,883 |
|---|---|
| Proxy Votes Against the Resolution | 1,657,736 |
| Proxy Votes Abstaining | 52,547 |
| Proxy Votes Exercised at the Discretion of the Proxy | 5,625 |
Resolution 2- Appointment of Lawler Partners, Chartered Accountants, as Auditor or the Company
Total number of proxy votes
| Proxy Votes for the Resolution | 45,453,752 |
|---|---|
| Proxy Votes Against the Resolution | 852,792 |
| Proxy Votes Abstaining | 302,547 |
| Proxy Votes Exercised at the Discretion of the Proxy | 6,700 |
Resolution 3 – Issue of shares to Andrew Goodall in lieu of loan repayment
Total number of proxy votes
| Proxy VotesfortheResolution | 23,515,363 |
|---|---|
| Proxy Votes Against the Resolution | 213,329 |
| ProxyVotes Abstaining | 22,881,474 |
| ProxyVotes Exercised at the Discretion of the Proxy | 5,625 |
ENDS
For more information please contact:
Contact: Swapna Keskar Company Secretary +61 2 8415 7300
NuSep Holdings Ltd
324 Burns Bay Rd
Postal Address
Contact Details
Telephone +61 2 8415 7300 Facsimile +61 2 8415 7399
Email [email protected] Web www.nusep.com ABN 33 120 047 556
P.O. Box 823 Lane Cove NSW 1595
Lane Cove NSW 2066
– 2 –
About NuSep
NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from Fraction to Function . The company has offices in both Sydney Australia and Atlanta, USA.
With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.
NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.
NuSep Products:
==> picture [11 x 8] intentionally omitted <==
==> picture [11 x 9] intentionally omitted <==
- Gels – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.
==> picture [11 x 8] intentionally omitted <==
==> picture [11 x 9] intentionally omitted <==
- Separation Instruments – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.
==> picture [11 x 9] intentionally omitted <==
==> picture [11 x 8] intentionally omitted <==
- Proteomics Software – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.
==> picture [11 x 9] intentionally omitted <==
==> picture [11 x 8] intentionally omitted <==
- Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.
For more information about NuSep please visit the company’s website www.NuSep.com
About PrIME Biologics Pte Ltd
PrIME Biologics is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. PrIME Biologics is currently a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). PrIME Biologics process is based on the Pr eparative I solation by M embrane E lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation.
The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. The PrIME has been shown to remove virus, bacteria, endotoxins and prions which cause ‘Mad Cow Disease’. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.
The initial application for the PrIME process will be the Currently Unprocessable Plasma which represents approximately 50% of all the plasma collected in many countries.